Latest News of NVS
Jim Cramer Says It Will Take Time For Novartis AG (NVS) To 'Get The Attention Of Investors'
By Yahoo! Finance |
2 days ago
Jim Cramer advocates for financial literacy in high schools, emphasizing the importance of understanding money. He offers advice to young investors, promoting early investing and risk-taking. Novartis...
Is Novartis AG (NVS) the Best Cancer Stock to Buy Now?
By Yahoo! Finance |
4 days ago
A list of the 10 Best Cancer Stocks includes Novartis AG as a top contender in the oncology market, set to reach over $470 billion by 2032. Novartis focuses on innovation in oncology and recently acqu...
Novartis AG (NVS): A Cheap Pharmaceutical Stock to Buy According to Short Sellers
By Yahoo! Finance |
1 week ago
Novartis AG (NYSE:NVS) is a Swiss pharma giant known for drugs like Scemblix and Kisqali. It ranks 4th among cheap pharmaceutical stocks. Its success hinges on innovative drugs and strategic marketing...
-
Annovis Bio, Inc. (NYSE:ANVS) surges 24%; retail investors who own 56% shares profited along with insiders
By Yahoo! Finance | 2 weeks agoRetail investors own a majority stake of 56% in Annovis Bio, giving them significant influence over management decisions. Institutional investors also hold a portion, indicating confidence in the comp...
-
Insider Buying: CEO Paul Keel Acquires Shares of Envista Holdings Corp (NVST)
By Yahoo! Finance | 3 weeks agoEnvista Holdings Corp, a healthcare company focusing on dental products, had an insider purchase of shares at $16.87, totaling approximately $506,100. CEO Paul Keel's significant stake increase sugges...
-
Insider Buying: CFO Eric Hammes Acquires Shares of Envista Holdings Corp (NVST)
By Yahoo! Finance | 3 weeks agoOn August 12, 2024, Envista Holdings Corp's CFO, Eric Hammes, purchased 24,532 shares of the company, totaling $400,000. The company focuses on dental products and technologies. With a market cap of $...
-
Novartis Ag (NVS) Q2 2024 Earnings Call Transcript
By Yahoo! Finance | 1 month agoNovartis recently released strong Q2 2024 results, showcasing an 11% growth in sales and a 19% increase in core operating income....
-
Novartis AG (NVSEF) Stock Price, News, Quote & History - Yahoo Finance
By Yahoo! Finance | 1 month agoNovartis AG is a Swiss-based company specializing in healthcare products, focusing on various therapeutic areas. It collaborates with other companies for the development of new therapies and digital s...
-
Novartis AG (NVS) Stock Price, News, Quote & History - Yahoo Finance
By Yahoo! Finance | 1 month agoNovartis AG is a Swiss-based company that researches, develops, and markets healthcare products globally, specializing in various therapeutic areas. They have collaborations for innovative treatments ...
-
Novartis AG (NVS) Stock Price, News, Quote & History
By Yahoo! Finance | 1 month agoNovartis AG is a Swiss-based company specializing in healthcare products, focusing on various therapeutic areas. It collaborates with other companies for the development of innovative therapies like i...
-
Here's Why Aristotle Capital's International Equity Composite Sold Novartis AG (NVS)
By Yahoo! Finance | 1 month agoAristotle Capital Management released its Q2 2024 investor letter, highlighting the performance of its International Equity Strategy. The letter discusses underperformance against market indices and m...
-
Annovis Bio, Inc. (ANVS) Stock Price, News, Quote & History
By Yahoo! Finance | 2 months agoAnnovis Bio is a drug platform company working on treatments for neurodegenerative diseases like Alzheimer's and Parkinson's. They have lead candidates in various stages of clinical trials, aiming to ...
-
Annovis Bio, Inc. (ANVS) Stock Price, News, Quote & History - Yahoo Finance
By Yahoo! Finance | 2 months agoAnnovis Bio's Phase III Parkinson's study shows promising results with buntanetap treatment, leading to improvements in UPDRS and cognition....
-
ANVS Stock Price | Annovis Bio Inc. Stock Quote (U.S.: NYSE) | MarketWatch
By MarketWatch | 2 months agoAnnovis Bio, Inc. is a drug platform company developing treatments for neurodegenerative diseases like Alzheimer's and Parkinson's. Their lead candidate, Buntanetap, targets AD, PD, and other neurodeg...